We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

115 hedge funds and large institutions have $992M invested in Aurinia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

629% more capital invested

Capital invested by funds: $136M → $992M (+$856M)

550% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 8

127% more call options, than puts

Call options by funds: $89.1M | Put options by funds: $39.3M

60% more funds holding

Funds holding: 72 → 115 (+43)

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

17.96% more ownership

Funds ownership: 27.74% → 45.7% (+18%)

Holders
115
Holders Change
+43
Holders Change %
+59.72%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.12%
New
52
Increased
28
Reduced
19
Closed
8
Calls
$89.1M
Puts
$39.3M
Net Calls
+$49.8M
Net Calls Change
+$49.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$63.6M
2
CCM
Consonance Capital Management
New York
+$37.4M
3
HM
HealthCor Management
New York
+$36.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$32.9M
5
BBA
Baker Bros. Advisors
New York
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
-$17.7M
2
O
OrbiMed
New York
-$10.9M
3
Goldman Sachs
Goldman Sachs
New York
-$9.5M
4
Ameriprise
Ameriprise
Minnesota
-$1.96M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
26
Creative Planning
Kansas
$5.38M +$525K +57,000 +27%
Morgan Stanley
27
Morgan Stanley
New York
$4.97M +$2.03M +220,854 +904%
APM
28
Avidity Partners Management
Texas
$4.7M +$2.14M +232,000 New
MS
29
Maven Securities
Jersey
$4.37M +$1.98M +214,673 New
Allianz Asset Management
30
Allianz Asset Management
Germany
$4.37M +$1.98M +215,440 New
Group One Trading
31
Group One Trading
Illinois
$3.46M +$956K +103,767 +155%
EGI
32
EAM Global Investors
California
$3.24M +$1.47M +159,984 New
IIM
33
Ironwood Investment Management
Massachusetts
$3.1M -$91.8K -9,971 -6%
JGC
34
J. Goldman & Co
New York
$3.09M +$1.4M +152,518 New
Swiss National Bank
35
Swiss National Bank
Switzerland
$3.08M +$281K +30,500 +25%
Ameriprise
36
Ameriprise
Minnesota
$2.98M -$1.96M -212,250 -59%
PCM
37
Pinz Capital Management
New York
$2.76M +$1.25M +136,200 New
BCM
38
Burrage Capital Management
Massachusetts
$2.56M +$1.17M +126,533 New
Barclays
39
Barclays
United Kingdom
$2.12M +$314K +34,115 +49%
GPCM
40
Granite Point Capital Management
Massachusetts
$2.03M +$921K +100,000 New
PHP
41
Parkman Healthcare Partners
Connecticut
$2.03M +$921K +100,000 New
Rockefeller Capital Management
42
Rockefeller Capital Management
New York
$1.89M – – –
TCM
43
Tekla Capital Management
Massachusetts
$1.84M +$836K +90,788 New
BFM
44
Boothbay Fund Management
New York
$1.74M +$792K +85,928 New
UBS Group
45
UBS Group
Switzerland
$1.68M +$699K +75,906 +1,076%
Wells Fargo
46
Wells Fargo
California
$1.62M +$18.4K +2,000 +3%
Geode Capital Management
47
Geode Capital Management
Massachusetts
$1.55M +$107K +11,577 +18%
EAM
48
Erste Asset Management
Austria
$1.41M +$608K +66,000 New
Walleye Capital
49
Walleye Capital
New York
$1.39M +$632K +68,570 New
TI
50
Trexquant Investment
Connecticut
$1.34M +$611K +66,304 New
1
2
3 4 5

AUPH Hedge Fund Activity: Q4 2019 in Review

115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2019, worth a combined $992M — up 629% from $136M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AUPH positions and 8 closed out — a net gain of 44 holders — while 28 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Polar Capital, exiting entirely with an estimated $17.7M sold.

  • 115 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2019, up from 72 in Q3 2019.
  • Funds reported $992M of Aurinia Pharmaceuticals stock for Q4 2019, up 629% quarter-over-quarter.
  • 52 funds opened new Aurinia Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +44 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $63.6M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2019 was Polar Capital, an estimated $17.7M sold.

Based on aggregated 13F filings for Q4 2019.